# Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/secukinumab-a-human-anti-il-17a-monoclonal-antibody-for-moderate-to-severe-crohn/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Wolfgang Hueber,Bruce E. Sands,Steve Lewitzky,Marc Vandemeulebroecke,Walter Reinisch,Peter Higgins,Jan Wehkamp,Brian G. Feagan,Michael Yao,Marek Karczewski,Jacek Karczewski,Nicole Pezous,Stephan Bek,Gerard Bruin,Bjoern Mellgard,C Berger,Marco Londei,Arthur P. Bertolino,Gervais Tougas,Simon Travis,for the Secukinumab in Crohn's Disease Study Group |
| Citations | 1,511 |
| DOI | 10.1136/gutjnl-2011-301668 |
| Fields | Biochemistry, Genetics and Molecular Biology,Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/4902107 |
| OpenAlex ID | https://openalex.org/W2132784721 |
| PMID | 22595313 |
| Type | article |
| Year | 2012 |

## Paper authors

- [Jan Wehkamp](https://scholariq.org/researchers/jan-wehkamp/)

## Paper journal

- [Gut](https://scholariq.org/journals/gut/)

## Paper primary topic

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)

## Paper topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Autoimmune and Inflammatory Disorders](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.